[Allergic rhinoconjunctivitis]

Allergic rhinoconjunctivitis (AR) is an increasingly prevalent disease with considerable impact on daily activities, quality of life and the course of atopic comorbidities. In this review, we argue that the diagnosis should be based on detailed history and evidence of IgE-sensitisation. The severity can be assessed using a visual analogue scale (VAS), where scores less-than 5 indicate mild and ≥ 5 indicate moderate-to-severe disease, and treatment should be tailored accordingly. Intranasal corticosteroids remain first-line in moderate-to-severe AR, while allergen immunotherapy is the only disease-modifying option with long-term effects.